Answers are grounded in this paper and cite their sources.
Demonstrates that fluorodeoxyglucose alters lipid metabolism and impairs intracellular transport in cancer cells, suggesting potential utility as a chemotherapy adjuvant.
// Simona Kavaliauskiene 1, 2, 3 , Maria Lyngaas Torgersen 1, 2 , Anne Berit Dyve Lingelem 1, 2 , Tove Irene Klokk 1, 2 , Tuulia Lintonen 4 , Helena Simolin 4 , Kim Ekroos 4 , Tore Skotland 1, 2 , Kirsten Sandvig 1, 2, 3 1 Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway 2 Center for Cancer Biomedicine, Oslo University Hospital, Oslo, Norway 3 Department of Biosciences, University of Oslo, Oslo, Norway 4 Zora Biosciences, Espoo, Finland Correspondence to: Kirsten Sandvig, email: kirsten.sandvig@ibv.uio.no Keywords: Shiga toxin, glucosylceramide, lipidomics, intracellular transport, 2-fluoro-2-deoxy-D-glucose Received: April 25, 2016 Accepted: October 21, 2016 Published: November 04, 2016 ABSTRACT 2-fluoro-2-deoxy-D-glucose (FDG), labeled with 18 F radioisotope, is the most common imaging agent used for positron emission tomography (PET) in oncology. However, little is known about the cellular effects of FDG. Another glucose analogue, 2-deoxy-D-glucose (2DG), has been shown to affect many cellular functions, including intracellular transport and lipid metabolism, and has been found to improve the efficacy of cancer chemotherapeutic agents in vivo . Thus, in the present study, we have investigated cellular effects of FDG with the focus on changes in cellular lipids and intracellular transport. By quantifying more than 200 lipids from 17 different lipid classes in HEp-2 cells and by analyzing glycosphingolipids from MCF-7, HT-29 and HBMEC cells, we have discovered that FDG treatment inhibits glucosylceramide synthesis and thus reduces cellular levels of glycosphingolipids. In addition, in HEp-2 cells the levels and/or species composition of other lipid classes, namely diacylglycerols, phosphatidic acids and phosphatidylinositols, were found to change upon treatment with FDG. Furthermore, we show here that FDG inhibits retrograde Shiga toxin transport and is much more efficient in protecting cells against the toxin than 2DG. In summary, our data reveal novel effects of FDG on cellular transport and glycosphingolipid metabolism, which suggest a potential clinical application of FDG as an adjuvant for cancer chemotherapy.
No takes yet. Share an insight, caveat, or question.
Kavaliauskiene et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: